The United States Pharmacopeia Appeals Panel today remanded the revised USP General Chapter standards <795> for nonsterile compounding and <797> for sterile compounding to an expert committee “for further engagement on the issues raised concerning the beyond-use date provisions.” USP last year postponed the effective dates for these standards and for the new General Chapter <825> radiopharmaceuticals standard due to pending appeals. The appeals panel today denied the General Chapter <825> appeal, encouraging the appellant to submit a narrower request for revision to the expert committee. AHA had urged USP to delay the <797> standard due to implementation and compliance concerns. 

Today’s announcement will delay the effective date of the revised <797> chapter, as well as the effective date of General Chapter <800> on hazardous drug handling in health care settings. While <800> will remain informational pending final revisions to <797>, AHA advises members to contact their state boards of pharmacy regarding state-level effective dates for General Chapter <800>. AHA will update members with additional information as it becomes available.  
 

Headline
The House Ways and Means Committee July 1 voted along party lines to advance a bill, H.R. 9504, the Tax-Exempt Hospitals Transparency Act, that would add…
Headline
Elizabeth Mort, M.D., vice president and chief medical officer at Joint Commission, breaks down the five critical priorities boards must focus on — …
Blog
High-quality maternal care is essential to protecting the health of both mom and baby during birth.Sutter Health is taking a proactive, systemwide approach to…
Headline
USA Today published a column  by AHA Board Chair Marc Boom, M.D., president and CEO of Houston Methodist, highlighting how hospitals and health systems…
Headline
The Department of Health and Human Services published an interim final rule May 7 to delay compliance dates for entities receiving federal financial assistance…
Headline
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…